

19 September 2024

ASX Announcement

Island appoints Chris Ntoumenopoulos as Non-Executive Director

- **Mr Chris Ntoumenopoulos brings extensive financial markets experience to Island's Board, particularly in the healthcare sector**
- **Dr David Brookes retires from the Board**

MELBOURNE Australia, 19 September 2024: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to announce changes to its Board of Directors as part of its ongoing Board renewal process.

Mr Chris Ntoumenopoulos has been appointed Non-Executive Director. Mr Ntoumenopoulos has more than 20 years' financial markets experience and is the Managing Director at Twenty 1 Corporate, an Australian-based corporate advisory firm. He was a founding director of both ResApp Health Ltd (ASX:RAP), which was acquired by Pfizer, and Race Oncology (ASX:RAC). Currently, he serves as a Non-Executive Director at TrivarX Limited (ASX:TRI) and Tryptamine Therapeutics (ASX: TYP).

Mr Ntoumenopoulos' appointment is part of the Company's ongoing Board review and renewal process and in tandem Dr David Brookes will retire from the Board to focus on other business activities. Dr Brookes has served as a Non-Executive Director for nearly four years, including prior to the Company's initial public offering.

Commenting on the Board changes, Executive Chair, Dr Paul MacLeman said, *"I would like to extend my sincere gratitude to David for his longstanding commitment to Island. During his tenure, Island has continued to build and evolve its business strategy and strengthen its clinical pipeline, and I wish him all the best as he steps away to focus on other commitments."*

"I warmly welcome Chris to Island and I am excited about the contribution he will make given his deep experience in the financial markets and the domain experience he brings from many years as a director of ASX listed healthcare companies."

Mr Chris Ntoumenopoulos commented, *"This is an exciting time in the*



evolution of Island Pharmaceuticals, as the company launches its Phase 2a/b clinical trials amid a growing global need for dengue fever solutions. I have been impressed by the dedication of the team and look forward to helping realise the clinical and commercial potential of ISLA-101 and Island's developing pipeline."

To subscribe to Island's monthly newsletter, [IslandWatch](#), and other forms of email communications, please visit [this page](#) of our website.

Approved for release to the ASX by:

Dr Paul MacLeman
Executive Chairman
Island Pharmaceuticals Ltd
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue² fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.